Long-term effects of weight-reducing drugs in people with hypertension
- PMID: 26934640
- DOI: 10.1002/14651858.CD007654.pub4
Long-term effects of weight-reducing drugs in people with hypertension
Update in
-
Long-term effects of weight-reducing drugs in people with hypertension.Cochrane Database Syst Rev. 2021 Jan 17;1(1):CD007654. doi: 10.1002/14651858.CD007654.pub5. Cochrane Database Syst Rev. 2021. PMID: 33454957 Free PMC article.
Abstract
Background: All major guidelines on antihypertensive therapy recommend weight loss; anti-obesity drugs may be able to help in this respect.
Primary objectives: To assess the long-term effects of pharmacologically induced reduction in body weight in adults with essential hypertension on all-cause mortality, cardiovascular morbidity, and adverse events (including total serious adverse events, withdrawal due to adverse events, and total non-serious adverse events).
Secondary objectives: To assess the long-term effects of pharmacologically induced reduction in body weight in adults with essential hypertension on change from baseline in systolic blood pressure, change from baseline in diastolic blood pressure, and body weight reduction.
Search methods: We obtained studies using computerised searches of the Cochrane Hypertension Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Ovid EMBASE, the clinical trials registry ClinicalTrials.gov, and from handsearches in reference lists and systematic reviews (status as of 13 April 2015).
Selection criteria: Randomised controlled trials in hypertensive adults of at least 24 weeks' duration that compared long-term pharmacologic interventions for weight loss with placebo.
Data collection and analysis: Two review authors independently selected studies, assessed risk of bias, and extracted data. Where appropriate and in the absence of significant heterogeneity between studies (P > 0.1), we pooled studies using fixed-effect meta-analysis. When heterogeneity was present, we used the random-effects method and investigated the cause of heterogeneity.
Main results: After updating the literature search, which was extended to include four new weight-reducing drugs, we identified one additional study of phentermine/topiramate, bringing the total number of studies to nine that compare orlistat, sibutramine, or phentermine/topiramate to placebo and thus fulfil our inclusion criteria. We identified no relevant studies investigating rimonabant, liraglutide, lorcaserin, or naltrexone/bupropion. No study included mortality and cardiovascular morbidity as predefined outcomes. Incidence of gastrointestinal side effects was consistently higher in those participants treated with orlistat versus those treated with placebo. The most frequent side effects were dry mouth, constipation, and headache with sibutramine, and dry mouth and paresthaesia with phentermine/topiramate. In participants assigned to orlistat, sibutramine, or phentermine/topiramate body weight was reduced more effectively than in participants in the usual-care/placebo groups. Orlistat reduced systolic blood pressure as compared to placebo by -2.5 mm Hg (mean difference (MD); 95% confidence interval (CI): -4.0 to -0.9 mm Hg) and diastolic blood pressure by -1.9 mm Hg (MD; 95% CI: -3.0 to -0.9 mm Hg). Sibutramine increased diastolic blood pressure compared to placebo by +3.2 mm Hg (MD; 95% CI: +1.4 to +4.9 mm Hg). The one trial that investigated phentermine/topiramate suggested it lowered blood pressure.
Authors' conclusions: In people with elevated blood pressure, orlistat and sibutramine reduced body weight to a similar degree, while phentermine/topiramate reduced body weight to a greater extent. In the same trials, orlistat and phentermine/topiramate reduced blood pressure, while sibutramine increased it. We could include no trials investigating rimonabant, liraglutide, lorcaserin, or naltrexone/bupropion in people with elevated blood pressure. Long-term trials assessing the effect of orlistat, liraglutide, lorcaserin, phentermine/topiramate, or naltrexone/bupropion on mortality and morbidity are unavailable and needed. Rimonabant and sibutramine have been withdrawn from the market, after long-term trials on mortality and morbidity have confirmed concerns about the potential severe side effects of these two drugs. The European Medicines Agency refused marketing authorisation for phentermine/topiramate due to safety concerns, while the application for European marketing authorisation for lorcaserin was withdrawn by the manufacturer after the Committee for Medicinal Products for Human Use judged the overall benefit/risk balance to be negative.
Update of
-
Long-term effects of weight-reducing drugs in hypertensive patients.Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007654. doi: 10.1002/14651858.CD007654.pub3. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2016 Mar 02;3:CD007654. doi: 10.1002/14651858.CD007654.pub4. PMID: 23543553 Updated. Review.
Similar articles
-
Long-term effects of weight-reducing drugs in people with hypertension.Cochrane Database Syst Rev. 2021 Jan 17;1(1):CD007654. doi: 10.1002/14651858.CD007654.pub5. Cochrane Database Syst Rev. 2021. PMID: 33454957 Free PMC article.
-
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.JAMA. 2016 Jun 14;315(22):2424-34. doi: 10.1001/jama.2016.7602. JAMA. 2016. PMID: 27299618 Free PMC article. Review.
-
Long-term effects of weight-reducing drugs in hypertensive patients.Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007654. doi: 10.1002/14651858.CD007654.pub3. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2016 Mar 02;3:CD007654. doi: 10.1002/14651858.CD007654.pub4. PMID: 23543553 Updated. Review.
-
Long-term effects of weight-reducing drugs in hypertensive patients.Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007654. doi: 10.1002/14651858.CD007654.pub2. Cochrane Database Syst Rev. 2009. Update in: Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007654. doi: 10.1002/14651858.CD007654.pub3. PMID: 19588440 Updated. Review.
-
[Pharmacological therapy of obesity].G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. G Ital Cardiol (Rome). 2008. PMID: 18773755 Italian.
Cited by
-
Effects of an oral biodegradable device used for 12 weeks on weight reduction, cardiovascular risk factors, satiety, snacking, and meal size.Obes Pillars. 2023 Nov 13;8:100094. doi: 10.1016/j.obpill.2023.100094. eCollection 2023 Dec. Obes Pillars. 2023. PMID: 38125654 Free PMC article.
-
Anti-Adipogenic and Anti-Obesity Effects of Gongmi Tea and Gongmi So Extract.Prev Nutr Food Sci. 2023 Mar 31;28(1):21-29. doi: 10.3746/pnf.2023.28.1.21. Prev Nutr Food Sci. 2023. PMID: 37066032 Free PMC article.
-
Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs).Cureus. 2022 Dec 16;14(12):e32610. doi: 10.7759/cureus.32610. eCollection 2022 Dec. Cureus. 2022. PMID: 36654602 Free PMC article. Review.
-
Brevibacillus laterosporus BL1, a promising probiotic, prevents obesity and modulates gut microbiota in mice fed a high-fat diet.Front Nutr. 2022 Nov 24;9:1050025. doi: 10.3389/fnut.2022.1050025. eCollection 2022. Front Nutr. 2022. PMID: 36505236 Free PMC article.
-
Cyanidin-3-O-glucoside Regulates the Expression of Ucp1 in Brown Adipose Tissue by Activating Prdm16 Gene.Antioxidants (Basel). 2021 Dec 14;10(12):1986. doi: 10.3390/antiox10121986. Antioxidants (Basel). 2021. PMID: 34943089 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous